Form 4: Elicio Therapeutics Executive Acquires Stock Options

Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer of Elicio Therapeutics, acquired stock options on September 30, 2024.

Summary

• Christopher Haqq, an executive at Elicio Therapeutics, acquired 28,200 stock options on September 30, 2024.
• The exercise price of these options is $5.03.
• The options vest in two tranches: 50% on September 30, 2025, and the remaining 50% on September 30, 2026, contingent upon continued service to Elicio Therapeutics.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates continued investment in the company by an executive.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future prospects.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Elicio Therapeutics.
• Comparable companies such as Moderna or BioNTech also utilize stock options to incentivize their leadership teams.
• The vesting schedule of 50% after one year and the remaining 50% after two years is a fairly typical vesting schedule.

Stakeholder Impact

• The stock option grant could potentially incentivize the executive to improve company performance, benefiting shareholders.

Key Dates